Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) BTC-USD
67,884.51 +2,173.47 (+3.31%) CMC Crypto 200
1,375.05 +44.44 (+3.34%)
Bayer Aktiengesellschaft (BAYN.DE)
| Previous close | 27.53 |
| Open | 27.56 |
| Bid | 27.38 x 28400 |
| Ask | 27.39 x 2100 |
| Day's range | 27.18 - 27.60 |
| 52-week range | 24.96 - 53.80 |
| Volume | |
| Avg. volume | 3,156,281 |
| Market cap | 26.982B |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.17 |
| Earnings date | 06 Aug 2024 |
| Forward dividend & yield | 0.11 (0.40%) |
| Ex-dividend date | 29 Apr 2024 |
| 1y target est | 33.40 |
Associated Press FinanceMonsanto agrees to $160 million settlement with Seattle over pollution in the Duwamish River
Ending an eight-year legal battle, chemical giant Monsanto has agreed to a $160-million settlement with Seattle for its part in polluting a river that runs through the heart of the city with toxins that posed a threat to humans, fish and wildlife, the city attorney's office said Thursday. “We all play a role in protecting our environment and I am glad that Monsanto will contribute to this important environmental cleanup," City Attorney Ann Davison said in a news release. It's the largest single-city settlement Monsanto has paid, she said.
ReutersBayer's Monsanto to pay $160 million to resolve Seattle's PCB contamination lawsuit
Monsanto will pay $160 million to settle a lawsuit by the city of Seattle that accused the unit of Germany's Bayer of polluting the city's drainage system and the local Lower Duwamish River with toxic chemicals known as PCBs. In a statement, Monsanto said it will pay $35 million for PCB remediation, and $125 million to address other Seattle claims. Seattle accused Monsanto of creating a public nuisance by selling polychlorinated biphenyls for commercial use from 1935 to 1977 despite knowing they polluted the environment, harming people and wildlife.
ZacksBayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study
Bayer (BAYRY) meets the primary goal in the phase III study evaluating the darolutamide/ADT combo without docetaxel in metastatic hormone-sensitive prostate cancer patients.
